Early recognition and preventive care for persons being at risk for type 2 diabetes in community pharmacies in Bavaria, Germany

Not Applicable

• Conditions: E11; Type 2 diabetes mellitus

• Registration Number: DRKS00006585
• Lead Sponsor: WIPIG - Wissenschaftliches Institut für Prävention im Gesundheitswesen der Bayerischen Landesapothekerkammer

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2014-01-14
• Study Start: 2014-09-17
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 1140

Inclusion Criteria

increased risk for diabetes (FINDRISC score at least 7 points), ability to give written informed consent

Exclusion Criteria

diabetes, cancer, pregnancy, participation in a clinical trial 30 days prior to enrollment

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
FINDRISC score: Is there a significant difference of the change of the FINDRISC score between the intervention and the control group after 12 months?

Secondary Outcome Measures

Name	Time	Method
1) Weight loss (e.g., of at least 5% after 12 months in case of overweight at baseline)<br>2) Change of the capillary blood glucose level after 12 months<br>3) Change of the systolic and diastolic blood pressure after 12 months (non-invasive measurement)<br>4) Change of the physical activity after 12 months <br>5) Change of the quality of life after 12 months (SF-12 questionnaire)<br><br>For every secondary endpoint the comparison between the groups was analyzed.